Pliant Therapeutics To Participate In The Piper Sandler 32nd Annual Virtual Healthcare Conference

Rhea-AI Summary

Pliant Therapeutics (Nasdaq: PLRX) announced its participation in the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020. The company will feature a fireside chat with CEO Bernard Coulie on November 23, 2020, at 10:00 AM ET, available on their website. Pliant focuses on developing therapies for fibrosis, with lead candidate PLN-74809 in Phase 2a trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The session will be archived for 90 days post-event.

SOUTH SAN FRANCISCO, Calif., Nov. 19, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced its participation in the Piper Sandler 32nd Annual Healthcare Conference to be held virtually December 1 – 3, 2020.

Bernard Coulie, M.D., Ph.D., president and chief executive officer of Pliant Therapeutics, will participate in a fireside chat with Tyler M. Van Buren, senior biotechnology analyst at Piper Sandler. The fireside chat will be pre-recorded and available beginning on Monday, November 23, 2020 at 10:00 am ET by visiting the "News & Events" section of the "Investors & Media" page of the Pliant Therapeutics' website at www.pliantrx.com.

The webcast replay of the fireside chat will be archived for 90 days following the conclusion of the event.

About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of a_vß₆ and a_vß₁ integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 for the treatment of IPF and PSC. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of a_vß₁ for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter, LinkedIn, and Facebook.

Investor Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com

Media Contact:
Cambria Fuqua
Canale Communications
cambria.fuqua@canalecomm.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/pliant-therapeutics-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference-301176485.html

SOURCE Pliant Therapeutics, Inc.

FAQ

What is Pliant Therapeutics' stock symbol?

Pliant Therapeutics is traded under the stock symbol PLRX.

When is the Piper Sandler Healthcare Conference happening?

The Piper Sandler Healthcare Conference will take place from December 1-3, 2020.

Who will represent Pliant Therapeutics at the conference?

CEO Bernard Coulie will represent Pliant Therapeutics during the fireside chat.

When will the fireside chat be available to watch?

The fireside chat will be available on November 23, 2020, starting at 10:00 AM ET.

How long will the webcast be available after the event?

The webcast replay of the fireside chat will be archived for 90 days following the event.